L-arginine decreases inflammation and modulates the nuclear factor-κB/matrix metalloproteinase cascade in Mdx muscle fibers

American Journal of Pathology

Volumn 172, Issue 6, 2008, Pages 1509-1519

  Hnia, Karim ^a   Gayraud, Jérôme ^a   Hugon, Gérald ^a   Ramonatxo, Michèle ^a   De La Porte, Sabine ^b   Matecki, Stefan ^a   Mornet, Dominique ^a,c  

^a INSERM   (France)

^b LABORATOIRE DE NEUROBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA DYSTROGLYCAN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DUCHENNE MUSCULAR DYSTROPHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 44849127317     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.071009     Document Type: Article

References (50)

1. Deconinck N, Dan B: Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7
2. Koenig M, Hoffman PE, Bertelson JC, Monaco PA, Feener C, Kunkel ML: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50:509-517
3. Ibraghimov-Beskrovnaya O, Ervasti MJ, Leveille JC, Slaughter AC, Sernett WS, Campbell PK: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992, 355:696-702
4. Bulfield G, Siller GW, Wight AP, Moore JK: X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984, 81:1189-1192
5. Sicinski P, Geng Y, Ryder-Cook SA, Barnard AE, Darlison GM, Barnard JP: The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989, 244:1578-1580
6. Stedman HH, Sweeney LH, Shrager BJ, Maguire CH, Panettieri AR, Petrof B, Narusawa M, Leferovich MJ, Sladky TJ, Kelly MA: The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536-539
7. Tidball GJ, Wehling-Henricks M: The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007, 102:1677-1686
8. Yang XY, Muqit MM, Latchman SD: Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci 2006, 24:1366-1372
9. Ito Y, Oumi S, Nagasawa T, Nishizawa N: Oxidative stress induces phosphoenolpyruvate carboxykinase expression in H4IIE cells. Biosci Biotechnol Biochem 2006, 70:2191-2198
10. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier RA: TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 2007, 19:1419-1433
11. Lianxu C, Hongti J, Changlong Y: NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2. NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage 2006, 14:367-376
12. Kramer FH, Goodyear JL: Exercise, MAPK, and NF-{kappa}B signaling in skeletal muscle. J Appl Physiol 2007, 103:388-395
13. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici CM, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G: Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926
14. Kumar A, Lnu S, Malya R, Barron D, Moore J, Corry BD, Boriek MA: Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma. FASEB J 2003, 17:1800-1811
15. Kumar A, Boriek MA: Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 2003, 17:386-396
16. Monici CM, Aguennouz M, Mazzeo A, Messina C, Vita G: Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003, 60:993-997
17. Stuerenburg HJ, Jung R, Schoser GB: Age effects on interleukin-6 and interleukin-1beta responses to endurance exercise in patients with neuromuscular diseases. Arch Gerontol Geriatr 1999, 29:21-27
18. Durham JW, Arbogast S, Gerken E, Li PY, Reid BM: Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 2006, 34:298-303
19. Hodgetts S, Radley H, Davies M, Grounds DM: Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord 2006, 16:591-602
20. Archer DJ, Vargas CC, Anderson EJ: Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 2006, 20:738-740
21. Chazalette D, Hnia K, Rivier F, Hugon G, Mornet D: Alpha7B integrin changes in mdx mouse muscles after L-arginine administration. FEBS Lett 2005, 579:1079-1084
22. De Luca A, Nico B, Liantonio A, Didonna PM, Fraysse B, Pierno S, Burdi R, Mangieri D, Rolland FJ, Camerino C, Zallone A, Confalonieri P, Andreetta F, Arnoldi E, Courdier-Fruh I, Magyar PJ, Frigeri A, Pisoni M, Svelto M, Camerino CD: A multidisciplinary evaluation of the effectiveness of cyclosporine A in dystrophic mdx mice. Am J Pathol 2005, 166:477-489
23. Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar PJ: Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 2004, 14:675-682
24. Heussen C, Dowdle BE: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980, 102:196-202
25. Hnia K, Hugon G, Masmoudi A, Mercier J, Rivier F, Mornet D: Effect of beta-dystroglycan processing on utrophin/Dp116 anchorage in normal and mdx mouse Schwann cell membrane. Neuroscience 2006, 141:607-620
26. Wilson J, Putt W, Jimenez C, Edwards YH: Up71 and up140, two novel transcripts of utrophin that are homologues of short forms of dystrophin. Hum Mol Genet 1999, 8:1271-1278
27. Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D: Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol 2007, 170:633-643
28. Chaubourt E, Voisin V, Fossier P, Baux G, Israel M, Porte DLS: The NO way to increase muscular utrophin expression? C R Acad Sci III 2000, 323:735-740
29. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, Ramonatxo M, Israel M, Porte DLS: L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 2005, 20:123-130
30. Kabouridis SP, Hasan M, Newson J, Gilroy WD, Lawrence T: Inhibition of NF-kappa B activity by a membrane-transducing mutant of I kappa B alpha. J Immunol 2002, 169:2587-2593
31. Lang MJ, Esser AK, Dupont-Versteegden EE: Altered activity of signaling pathways in diaphragm and tibialis anterior muscle of dystrophic mice. Exp Biol Med (Maywood) 2004, 229:503-511
32. Kumar A, Takada Y, Boriek MA, Aggarwal BB: Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004, 82:434-448
33. Kumar A, Khandelwal N, Malya R, Reid BM, Boriek MA: Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004, 18:102-113
34. Acharyya S, Villalta AS, Bakkar N, Bupha-Intr T, Janssen MP, Carathers M, Li WZ, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner LK, Rafael-Fortney AJ, Karin M, Tidball GJ, Baldwin SA, Guttridge CD: Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007, 117:889-901
35. Chargé BS, Rudnicki AM: Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238
36. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663
37. Guttridge CD, Mayo WM, Madrid VL, Wang YC, Baldwin SA Jr: NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366
38. Long HJ, Lira AV, Soltow AQ, Betters LJ, Sellman EJ, Criswell SD: Arginine supplementation induces myoblast fusion via augmentation of nitric oxide production. J Muscle Res Cell Motil 2006, 27:577-584
39. Pisconti A, Brunelli S, Padova DM, Palma DC, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E: Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol 2006, 172:233-244
40. Buchwalow BI, Minin AE, Muller UF, Lewin G, Samoilova EV, Schmitz W, Wellner M, Hasselblatt M, Punkt K, Muller-Werdan U, Demus U, Slezak J, Koehler G, Boecker W: Nitric oxide synthase in muscular dystrophies: a re-evaluation. Acta Neuropathol (Berl) 2006, 111:579-588
41. Crosbie HR, Straub V, Yun YH, Lee CJ, Rafael AJ, Chamberlain SJ, Dawson LV, Dawson MT, Campbell PK: Mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998, 7:823-829
42. Zhuang W, Eby CJ, Cheong M, Mohapatra KP, Bredt SD, Disatnik HM, Rando AT: The susceptibility of muscle cells to oxidative stress is independent of nitric oxide synthase expression. Muscle Nerve 2001, 24:502-511
43. Wehling M, Spencer JM, Tidball GJ: A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001, 155:123-131
44. Mariotti F, Huneau JF, Szezepanski I, Petzke KJ, Aggoun Y, Tome D, Bonnet D: Meal amino acids with varied levels of arginine do not affect postprandial vascular endothelial function in healthy young men. J Nutr 2007, 137:1383-1389
45. Gillis MJ: An attempt of gene therapy in Duchenne muscular dystrophy: overexpression of utrophin in transgenic mdx mice. Acta Neurol Belg 2000, 100:146-150
46. Ebihara S, Guibinga HG, Gilbert R, Nalbantoglu J, Massie B, Karpati G, Petrof JB: Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol Genomics 2000, 3:133-144
47. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, Spitali P, Rimessi P, Gualandi F, Sewry C, Ferlini A, Muntoni F: Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 2007, 17:913-918
48. Rentschler S, Linn H, Deininger K, Bedford TM, Espanel X, Sudol M: The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan. Biol Chem 1999, 380:431-442
49. Hnia K, Zouiten D, Cantel S, Chazalette D, Hugon G, Fehrentz AJ, Masmoudi A, Diment A, Bramham J, Mornet D, Winder JS: ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. Biochem J 2007, 401:667-677
50. Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies EK, Ozawa E: ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum Mol Genet 2004, 13:693-702